Proteasome inhibitor patents (2010 - present)

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Proteasome inhibition is a key strategy in cancer research, targeting protein degradation pathways.
• Current FDA-approved proteasome inhibitors (bortezomib, carfilzomib) face challenges with toxicity and resistance.
• Numerous patents focus on improving existing proteasome inhibitors' bioavailability, selectivity, and reducing toxicity.

Purpose of the Study:

• To review and categorize novel proteasome inhibitor compounds and analogs from recent patents.
• To evaluate the design strategies and therapeutic potential of these compounds in cancer treatment.
• To analyze combination therapy patents involving proteasome inhibitors.

Main Methods:

• Comprehensive review and categorization of patents related to proteasome inhibitors.
• Analysis of compound derivatives, their anticancer uses, and efficacies.
• Inclusion of a review of combination therapy patents.

Main Results:

• A wide array of chemical scaffolds for proteasome inhibition are being patented.
• Most patented inhibitors employ a destructive warhead targeting the proteasome's active site.
• Limited novelty exists in the mechanism of action across patented compounds.

Conclusions:

• The majority of patented proteasome inhibitors do not introduce novel mechanisms of action.
• There is a significant need for developing proteasome inhibitors with new mechanisms and specific targeting strategies.
• Further innovation is required to overcome limitations of current proteasome-targeted cancer therapies.